Mónica A. G.
- Country
- Spain
- Department
- Allergy
Research Overview
- Subcutaneous Dermatophagoides/Lepidoglyphus immunotherapy for moderate-to-severe allergic rhinitis/rhinoconjunctivitis with mild-to-moderate asthma: randomized placebo-controlled trial
- Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Evaluating Subcutaneous Immunotherapy with Cupressus arizonica Protein Cup a 1 in Allergic Rhinoconjunctivitis
- Evaluation of the Efficacy and Safety of Mannan-Conjugated Allergoids in Moderate-to-Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Controlled Asthma
Data & Insights
Has run more than one trial at 4 of 32 partner sites.
Specializations
Allergic Respiratory Conditions
The investigator specializes in treating allergic rhinoconjunctivitis and allergic asthma, with particular emphasis on developing innovative immunotherapy approaches.
- Moderate to severe rhinitis management
- Persistent rhinoconjunctivitis treatment
- Controlled asthma therapy
Their research encompasses both intermittent and persistent forms of these conditions.
Allergen-Specific Immunotherapy
The investigator focuses on developing targeted treatments for specific allergens, including Cupressaceae pollen and house dust mites.
- Subcutaneous immunotherapy protocols
- Polymerized allergen extracts
- Mannan-conjugated allergoids
Their work involves innovative protein-based immunotherapy approaches using purified allergens.
Therapeutic Applications
The investigator develops aetiological treatments for allergic conditions, focusing on both symptomatic relief and underlying cause modification.
- Immunotherapy efficacy assessment
- Novel allergen delivery systems
- Combined respiratory condition management
Their research addresses both isolated allergic conditions and cases with concurrent asthma.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.